This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.
Atul Khajuria,
Ashish Kumar 2,,
Pradeep Singh 3,
- Dean, Department of Allied & Health Care Sciences, Rayat Bahra Professional University, Hoshiarpur, Chandigarh Rd, VPO, Bohan, Hoshiarpur, Punjab, India
- Faculty, Department of Allied & Health Care Sciences, Rayat Bahra Professional University Hoshiarpur – Chandigarh Rd, VPO, Bohan, Hoshiarpur, punjab, India
- Faculty, Department of Allied & Health Care Sciences, Rayat Bahra Professional University Hoshiarpur – Chandigarh Rd, VPO, Bohan, Hoshiarpur, punjab, India
Abstract
Histoplasmosis is a systemic mycosis caused by the thermally dimorphic fungus Histoplasma capsulatum. Infection is acquired primarily by inhalation of infectious microconidia and may range from asymptomatic infection to severe disseminated disease. Although histoplasmosis has classically been associated with the river valleys of the Americas, it is being increasingly recognized in Asia, including India, where it frequently mimics tuberculosis, leishmaniasis, lymphoma, and leprosy, resulting in delayed diagnosis and treatment. Cutaneous and mucocutaneous manifestations are of particular importance because they may provide the earliest visible clue to systemic infection in both immunocompetent and immunocompromised patients. In India, histoplasmosis was previously considered to be limited mainly to the Gangetic belt. However, recent reports from Himachal Pradesh, Kerala, and other non-Gangetic regions suggest a wider ecological distribution and an increasing clinical burden. Adrenal involvement, progressive disseminated histoplasmosis, and mucocutaneous disease have been reported prominently in Indian cohorts, especially among people living with HIV, transplant recipients, and patients receiving corticosteroids or other immunosuppressive therapy. This review summarizes the current understanding of the biology, virulence mechanisms, epidemiology, clinical manifestations, laboratory diagnosis, and management of H. capsulatum, with special emphasis on Indian data.
Keywords: Keywords: Cutaneous manifestations, Histoplasma capsulatum, Histoplasmosis, India epidemiology, Mucocutaneous lesions, Progressive disseminated histoplasmosis, Thermal dimorphism.
Atul Khajuria, Ashish Kumar 2,, Pradeep Singh 3. Histoplasma capsulatum (Dimorphic Fungus) in India: Biological Features, Virulence Mechanisms, and Clinical Implications of Histoplasmosis.. International Journal of Fungi. 2026; 03(01):-.
Atul Khajuria, Ashish Kumar 2,, Pradeep Singh 3. Histoplasma capsulatum (Dimorphic Fungus) in India: Biological Features, Virulence Mechanisms, and Clinical Implications of Histoplasmosis.. International Journal of Fungi. 2026; 03(01):-. Available from: https://journals.stmjournals.com/ijf/article=2026/view=239721
References
1. Chatterjee S, Singh A, Gupta N, et al. Histoplasmosis in India: clinical insights from a tertiary care hospital. J Med Mycol. 2025;35(4):215224.
2. Kauffman CA. Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev. 2007;20(1):115132.
3. Wheat LJ, Azar MM, Bahr NC, Spec A, Relich RF, Hage C. Histoplasmosis. Infect Dis Clin North Am. 2016;30(1):207227.
4. Goodwin RA Jr, Des Prez RM. State of the art: histoplasmosis. Am Rev Respir Dis. 1978;117(5):929956.
5. Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45(7):807825.
6. IDSA. Histoplasmosis: 2025 clinical practice guideline update. Infectious Diseases Society of America; 2025.
7. Giri S, Raut A, Sharma A, et al. Disseminated histoplasmosis in India presenting as progressive wasting and adrenal involvement: a case series. Int J Infect Dis. 2020;96:6571.
8. Gupta N, Sharma A, Singh P, et al. Histoplasmosis: a rare cause of granulomatous cutaneous disease. Asian J Res Infect Dis. 2026;12(1):3440.
9. Dogra S, Kumar B, Radotra BD, Chakrabarti A. Primary cutaneous histoplasmosis in an immunocompetent host from a nonendemic region. Indian J Dermatol Venereol Leprol. 1994;60(6):331333.
10. Gupta R, Thakur K, Sharma S, et al. A rare case of disseminated cutaneous histoplasmosis. Indian J Dermatol Venereol Leprol. 2022;88(4):496500.
11. Singh P, Badwal S, Singh K, et al. Case report: histoplasmosis in Himachal Pradesh (India). Case Rep Infect Dis. 2017;2017:16.
12. Thappa DM, Karthikeyan K, Jeevankumar B, et al. Disseminated cutaneous histoplasmosis in an immunocompetent adult. Indian J Dermatol Venereol Leprol. 2005;71(3):187189.
13. Ahmed M, Prakash P, Saini A, et al. Disseminated cutaneous histoplasmosis and its recurrence in an apparently immunocompetent adult: a case report. Cureus. 2024;16(5):e58231.
14. Singh R, Gupta S, Arora S, et al. Cutaneous histoplasmosis: an unusual presentation with nasal obstruction. J Trop Med. 2020;2020:14.
15. Tharakan J, Mani S, Kuruvila S, et al. African histoplasmosis: the first report of an indigenous case in India. Int J Dermatol. 2015;54(12):e553e557.
16. Padhye AA, Pathak AA, Katkar VJ, et al. Histoplasmosis in India: a case report and review. Med Mycol. 2013;51(7):774778.
17. Gugnani HC. A review of histoplasmosis in India. J Infect Dev Ctries. 2014;8(12):15131519.
18. Singh A, Nair A, Kumar N, et al. Primary cutaneous histoplasmosis: report of two cases and review of Indian literature. J Lab Physicians. 2016;8(1):6266.
19. GAFFI. Histoplasmosis: GAFFI briefing note. Global Action Fund for Fungal Infections; 2020.
20. Adenis A, Nacher M, Hanf M, et al. HIVassociated histoplasmosis early mortality and incidence trends: from neglect to priority. PLoS Negl Trop Dis. 2014;8(8):e3100.
21. Nair A, Anitha A, George AM, et al. Histoplasmosis among immunocompromised patients: a review of Indian experience. Postgrad Med J. 2021;97(1149):607615.
22. Gupta N, Singh A, Kaur S, et al. Histoplasmosis in different age groups and alternative treatment approaches. J Fungi (Basel). 2023;9(2):150.
23. Hage CA, Ribes J, Wengenack NL, et al. Laboratory diagnostics for histoplasmosis. J Clin Microbiol. 2011;49(2):320–326.
24. CDC. Testing algorithm for histoplasmosis. Centers for Disease Control and Prevention; 2025.
25. Azar MM, Hage CA. Diagnostic methods for histoplasmosis: focus on endemic areas where HIV is prevalent. Clin Chest Med. 2017;38(3):425438.
26. Azar MM, Assi R, Relich RF, et al. Evolving epidemiology, improving diagnostic tests and their impact on histoplasmosis. Clin Infect Dis. 2025;70(6):e1e10.
International Journal of Fungi
| Volume | 03 |
| 01 | |
| Received | 13/02/2026 |
| Accepted | 25/03/2026 |
| Published | 27/03/2026 |
| Publication Time | 42 Days |
Login
PlumX Metrics